Lakewood Amedex
Lakewood Amedex, a private development stage biopharmaceutical company, headquartered in Sarasota, Florida, has a diverse portfolio of targeted therapeutics, broad spectrum anti-bacterials, and anti-viral technologies. The lead product, LPI007, is a fully human toxin-neutralizing monoclonal antibody shown to be effective in the treatment of hemolytic uremic syndrome (HUS) caused by pathogenic EcoliO157:H7 and will be entering Phase I clinical trials in late 2008. Nubiotics are a broad spectrum first in class group of anti-bacterial compounds that represent a first line defense against the increasing number of antibiotic resistant bacteria. A proprietary nanoRNA technology developed for the treatment of viral diseases, such as avian influenza and hepatitis.
OncoMed PharmaceuticalsOncoMed Pharmaceuticals was founded in August 2004, by Drs. Michael F. Clarke and Max Wicha who led the discovery of cancerstem cells, in solid tumors. The ability to isolate and monitor tumor initiating cells using specific surface markers and flow cytometry has allowed OncoMed to carefully evaluate the importance of specific targets associated with key biologic pathways implicated in both stem cell biology and cancer. Antibodies against these targets have been developed and tested within xenograft models derived from freshly resected human cancers. Using these approaches, OncoMedhas a portfolio of active antibodies that target biologic pathways critical for survival of tumor initiating cells. OncoMed's first antibody targeting the pathways critical to cancerstem cells has now entered clinical trials. Details of the initial Phase I study, which is now recruiting patients, may be found at ClinicalTrials.gov. Multiple additional promising therapeutic candidates that target other critical pathways are also being developed. OncoMed Pharmaceuticals has attracted significant funding from a prominent group of investors, that include, US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Nomura Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures and Bay Partners.